摘要：

A compound of formula (I) B2N-X-[CH2]m-C(R1)(R2)-C(=O)-Y and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy, or protected hydroxamic acid derivatives thereof wherein: m is 0-2; X is S(O)1-2; Y is OH or NHOH; R1 is H or optionally substituted alkyl, alkenyl, aryl, alkyl-aryl, heteroaryl, alkyl-heteroaryl, heterocycloalkyl, alkylheterocycloalkyl, cycloalkyl or alkyl-cycloalkyl; R2 is H or alkyl or CR1R2 is an optionally substituted cycloalkyl or heterocycloalkyl ring or an optionally substituted group alkyl, aryl, alkyl-aryl, heteroaryl or alkyl-heteroaryl; each B is independently H or optionally substituted alkyl-aryl, alkyl, cycloalkyl, alkyl-cycloalkyl, cycloalkenyl, heterocycloalkenyl, alkyl-heteroaryl, heterocycloalkyl, alkyl-heterocycloalkyl, aryl or heteroaryl, provided that NB2 is not NH2 or B-N-B is a heterocycloalkyl ring substituted with =O or =NOR4 or when neither R1 nor R2 is H, B-N-B is an optionally substituted heterocycloalkyl or heterocyclalkenyl; R4 is H or optionally substituted alkyl, aryl, alkyl-aryl, heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyl-cycloalkyl, heterocycloalkyl or alkylheterocycloalkyl, and for each case of N(R4)2 the R4 groups are the same or different or N(R4)2 is an optionally substituted heterocycloalkyl provided that when Y is OH, B-N-B is optionally substituted heterocycloalkyl and/or CR1R2 is optionally substituted cycloalkyl or heterocycloalkyl. A pharmaceutical composition thereof is useful in treating or preventing of a condition associated with matrix metalloproteinases or that is mediated by TNFa or enzymes involved in the shedding of L-selectin, CD23, the TNF receptors, IL-6 receptors or IL-1 receptors.

展开